Amplitude Inc
For the period ended Sep 30, 2024. Filed Nov 7, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 7, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Notes to Condensed Consolidated Financial Statements
(1)
Summary of Business and Significant Accounting Policies
Description of Business
Amplitude, Inc. (the “Company”) was incorporated in the state of Delaware in 2011 and is headquartered in San Francisco, California. The Company provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (“SaaS”) model. The Company’s arrangements with customers do not provide the customer with the right to take possession of the software supporting the cloud-based application service at any time. The Company also offers customer support related to initial implementation setup, ongoing support services, and application training.
Segment Information
The Company has asingle operating and reportable segment. The Company’s chief operating decision maker is its Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of making operating decisions, assessing financial performance, and allocating resources. Long-lived assets outside of the United States are immaterial. For information regarding the Company’s revenue by geographic area, see Note 2 below.
Basis of Presentation and Principles of Consolidation
The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP” or “GAAP”) and include the accounts of Amplitude, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The reporting currency of the Company is the United States dollar. The functional currency of the Company’s foreign subsidiaries is also the United States dollar.
The unaudited condensed consolidated balance sheet as of December 31, 2023 included herein was derived from the audited financial statements as of that date, but does not include all disclosures, including certain notes required by U.S. GAAP on an annual reporting basis. In management’s opinion, the unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to state fairly the balance sheet, statements of operations and comprehensive loss, statements of stockholders’ equity, and statements of cash flows for the interim periods, but are not necessarily indicative of the results of operations to be anticipated for the full fiscal year or any future period.
These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “2023 Form 10-K”).
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. These estimates are based on information available as of the date of the financial statements and may involve subjective or significant judgment by the Company; therefore, actual results could differ from the Company’s estimates. Items subject to such estimates and assumptions include, but are not limited to the:
expected period of benefit for deferred commissions;
useful lives of long-lived assets;
valuation of goodwill and intangible assets;
recognition, measurement, and valuation of deferred tax assets and income tax uncertainties; and
incremental borrowing rates used for operating leases.
Concentration of Risk and Significant Customers
Financial instruments that subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash, marketable securities, and accounts receivable. Although the Company deposits its cash with high-quality, credit-rated financial institutions, the deposits, at times, may exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.
No customer accounted for 10% or more of total revenue for thethree and nine months ended September 30, 2024 and 2023. As of September 30, 2024, no customer represented 10% or more of accounts receivable. As of December 31, 2023, one customer represented 10% of accounts receivable.
Significant Accounting Policies
The Company's significant accounting policies are described in the 2023 Form 10-K. There have been no significant changes to these policies that have had a material impact on the Company’s condensed consolidated financial statements and related notes for the three and nine months ended September 30, 2024.
Recently Issued Accounting Pronouncements
Segment Reporting: In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. All disclosure requirements of ASU 2023-07 are required for entities with a single reportable segment. The new standard will be effective for the Company for the annual periods beginning January 1, 2024, and for interim periods beginning January 1, 2025. Upon adoption, the guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adoption of the standard on disclosures within its consolidated financial statements.
Income Taxes: In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and income taxes paid. The amendment in the ASU is intended to enhance the transparency and decision usefulness of income tax disclosures. The amendments in this ASU are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of the new standard on its consolidated financial statements which is expected to result in enhanced disclosures.
(2)
Revenue from Contracts with Customers
Deferred Revenue and Remaining Performance Obligations
The amount of revenue recognized in the nine months ended September 30, 2024 that was included in deferred revenue as of December 31, 2023 was$98.6 million.
As of September 30, 2024 and December 31, 2023, unrecognized transaction price related to remaining performance obligations was$286.6 million and$239.4 million, respectively. The Company’s remaining performance obligations as of September 30, 2024 and December 31, 2023 are expected to be recognized as follows (in thousands):
| As ofSeptember 30, 2024 | As ofDecember 31,2023 | |
|---|---|---|
| Less than or equal to 12 months | $211,084 | $188,456 |
| Greater than 12 months | 75,525 | 50,962 |
| Total remaining performance obligations | $286,609 | $239,418 |
Disaggregation of Revenue
The following table shows the Company’s disaggregation of revenue by geographic areas, as determined based on the address of the Company's customers (in thousands):
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| United States | $45,176 | $42,748 | $132,730 | $124,937 |
| International | 30,041 | 27,889 | 88,411 | 79,944 |
| Total revenue | $75,217 | $70,637 | $221,141 | $204,881 |
Deferred Commissions
Commissions paid upon the initial acquisition of a contract are deferred and then amortized on a straight-line basis over a period of benefit, determined to befive years. The following table represents a roll forward of the Company’s deferred commissions for thethree and nine months ended September 30, 2024 and 2023 (in thousands):
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Beginning balance | $38,258 | $37,531 | $38,386 | $36,717 |
| Additions to deferred commissions | 5,997 | 2,983 | 12,656 | 9,458 |
| Amortization of deferred commissions | (3,651) | (3,103) | (10,438) | (8,764) |
| Ending balance | 40,604 | 37,411 | 40,604 | 37,411 |
| Deferred commissions, current portion | 14,312 | 12,294 | 14,312 | 12,294 |
| Deferred commissions, net of current portion | 26,292 | 25,117 | 26,292 | 25,117 |
| Total deferred commissions | $40,604 | $37,411 | $40,604 | $37,411 |
(3)
Balance Sheet Components
The following tables show the Company’s financial statement details as of September 30, 2024 and December 31, 2023.
Cash, Cash Equivalents and Restricted Cash
The following table represents the Company's cash, cash equivalents, and restricted cash at each period end (in thousands):
| As of September 30, · As of December 31, | ||||
|---|---|---|---|---|
| 2024 | 2023 | 2023 | 2022 | |
| Cash and cash equivalents | $317,448 | $238,525 | $248,491 | $218,494 |
| Restricted cash, current | 878 | — | — | — |
| Restricted cash, noncurrent | — | 865 | 869 | 855 |
| Total cash, cash equivalents, and restricted cash | $318,326 | $239,390 | $249,360 | $219,349 |
Prepaid Expenses and Other Current Assets
Prepaid expenses and other current assets consisted of the following (in thousands):
| As of September 30, | As of December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Prepaid hosting | $10,804 | $6,074 |
| Other prepaid expenses and other assets | 12,857 | 10,550 |
| Total prepaid expense and other current assets | $23,661 | $16,624 |
Accrued Expenses
Accrued expenses consisted of the following (in thousands):
| As of September 30, | As of December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Accrued hosting | $7,456 | $6,506 |
| Accrued commission and bonus | 12,801 | 6,383 |
| Accrued payroll and employee related taxes | 2,790 | 2,468 |
| Accrued sales tax | 414 | 322 |
| 2021 Employee Stock Purchase Plan withholding | 2,151 | 1,017 |
| Operating lease liabilities, current | 4,088 | 4,571 |
| Other accrued liabilities | 5,091 | 5,390 |
| Total accrued expenses | $34,791 | $26,657 |
(4)
Fair Value Measurements
The following table summarizes, for financial assets measured at fair value, the respective fair value and classification by level of input within the fair value hierarchy (in thousands):
| Amortized Cost · Gross Unrealized Gains · Gross Unrealized Losses · Estimated Fair Value | ||||||||
|---|---|---|---|---|---|---|---|---|
| Level 1: | ||||||||
| Cash equivalents(1) | ||||||||
| Money market funds | $ | 294,612 | $ | — | $ | — | $ | 294,612 |
| Level 2: | ||||||||
| Available-for-sale securities | ||||||||
| U.S. governmental securities | 2,496 | — | — | 2,496 | ||||
| Total | $ | 297,108 | $ | — | $ | — | $ | 297,108 |
| Amortized Cost · Gross Unrealized Gains · Gross Unrealized Losses · Estimated Fair Value | ||||||||
|---|---|---|---|---|---|---|---|---|
| Level 1: | ||||||||
| Cash equivalents(1) | ||||||||
| Money market funds | $ | 211,741 | $ | — | $ | — | $ | 211,741 |
| Level 2: | ||||||||
| Available-for-sale securities | ||||||||
| U.S. governmental securities | 74,090 | — | (181) | 73,909 | ||||
| Total | $ | 285,831 | $ | — | $ | (181) | $ | 285,650 |
(1)
Included in “Cash and cash equivalents” in the Company’s condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023, in addition to cash of$22.8 million and$36.8 million, respectively.
The Company uses quoted prices in active markets for identical assets to determine the fair value of the Company's Level 1 investments. The fair value of the Company's Level 2 investments is determined using pricing based on quoted market prices or alternative market observable inputs.
The fair value of the Company's available-for-sale securities as of September 30, 2024, by remaining contractual maturities, was as follows (in thousands):
| Due in one year or less | $2,496 |
|---|---|
| Due in greater than one year | — |
| Total | $2,496 |
(5)
Stockholders’ Equity and Equity Incentive Plans
Preferred stock
In connection with the direct listing of the Company’s Class A common stock on the Nasdaq Capital Market (the “Direct Listing”) on September 21, 2021, an amended and restated certificate of incorporation of the Company was filed with the Secretary of State of the State of Delaware, which authorized the issuance of 20 million shares of undesignated preferred stock with a par value of $0.00001 per share and rights and preferences, including voting rights, designated from time to time by the Company's board of directors.
Common Stock
The Company has two classes of common stock: Class A common stock and Class B common stock. The Company's amended and restated certificate of incorporation authorizes the issuance of 600 million shares of Class A common stock and 600 million shares of Class B common stock. The shares of Class A common stock and Class B common stock are identical, except with respect to voting, conversion, and transfer rights. Each share of Class A common stock is entitled to one vote. Each share of Class B common stock is entitled to five votes. Class A and Class B common stock each have a par value of $0.00001 per share, and are referred to as common stock throughout the notes to the condensed consolidated financial statements, unless otherwise noted. Holders of common stock are entitled to receive any dividends whenever funds are legally available and if declared by the Company's board of directors.
Shares of Class B common stock may be converted to Class A common stock at any time at the option of the stockholder. Shares of Class B common stock will also automatically convert into one share of Class A common stock upon any transfer, except for certain permitted transfers described in the Company's amended and restated certificate of incorporation. In addition, each share of Class B common stock held by the Company's three cofounders (or any of such founder’s affiliates) will convert automatically into one share of Class A common stock on the earlier of: (i) the death or incapacity of such founder or (ii) the date that is six months following the date on which such founder is no longer an employee or director of the Company (unless such founder has rejoined the Company during such six-month period). Each outstanding share of the Company's Class B common stock will also convert automatically into one share of Class A common stock on the date that is six months following the date on which no founder is an employee or director of the Company (unless a founder has rejoined the Company during such six-month period). In addition, any transfer by a founder (or such founder’s affiliates) to one or more of the other founders (or such founders’ affiliates) will not result in the automatic conversion of such shares of Class B common stock to Class A common stock. Once converted into Class A common stock, the Class B common stock may not be reissued.
The Company has reserved shares of its common stock as follows:
| As ofSeptember 30, 2024 | As ofDecember 31, 2023 | |
|---|---|---|
| 2014 Stock Option and Grant Plan and 2021 Incentive Award Plan: | ||
| Equity plan stock options outstanding | 11,746,402 | 14,268,055 |
| RSUs outstanding | 12,958,603 | 11,301,279 |
| Shares available for future issuance | 19,960,263 | 18,260,813 |
| 2021 Employee Stock Purchase Plan: | ||
| Shares available for future issuance | 5,024,397 | 4,079,994 |
| Total reserved shares | 49,689,665 | 47,910,141 |
Equity Incentive Plans
2014 Stock Option and Grant Plan
In December 2014, the Company adopted its 2014 Stock Option and Grant Plan (as amended, the “2014 Plan”), pursuant to which shares of the Company’s common stock were reserved for the issuance of stock options (incentive and non-statutory), restricted stock units (“RSUs”), and restricted stock to employees, directors, and consultants under terms and provisions established by the Company's board of directors and approved by the Company’s stockholders. The 2014 Plan was terminated in September 2021 in connection with the Direct Listing but continues to govern the terms of outstanding awards that were granted prior to the termination of the 2014 Plan. No further equity awards will be granted under the 2014 Plan. With the establishment of the 2021 Incentive Award Plan (the “2021 Plan”) as further discussed below, upon the expiration, forfeiture, cancellation, or reacquisition of any shares of Class A common stock underlying outstanding stock-based awards granted under the 2014 Plan, an equal number of shares of Class A common stock will become available for grant under the 2021 Plan.
2021 Incentive Award Plan
In August 2021, the Company's board of directors adopted, and its stockholders approved, the 2021 Plan, which became effective in connection with the Direct Listing. The 2021 Plan provides for the grant of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, RSU awards, performance bonus awards, performance stock units, dividend equivalent awards and other forms of equity compensation (collectively, “equity awards”). As of September 30, 2024, a total of 19,960,263 shares of the Company's Class A common stock have been reserved for issuance under the 2021 Plan in addition to (i) any shares available for issuance under the 2014 Plan as of the effective date of the 2021 Plan, (ii) the number of shares represented by awards outstanding under the Company's 2014 Plan (“Prior Plan Awards”) that become available upon the expiration, forfeiture, cancellation, or reacquisition of any shares of Class A common stock underlying outstanding stock awards granted under the 2014 Plan, and (iii) an annual increase on the first day of each fiscal year beginning in 2022 and ending in 2031, equal to the lesser of (A) 5% of the shares of the Company's common stock outstanding (on an as-converted basis) on the last day of the immediately preceding fiscal year and (B) such smaller number of shares of stock as determined by the Company's board of directors; provided, however, that no more than 88,000,000 shares of stock may be issued upon the exercise of incentive stock options.
Stock Option Awards
Stock options granted under the 2014 Plan and the 2021 Plan (collectively, the “combined stock plans”) generally vest based on continued service over four years.
Option activity under the combined stock plans for thenine months ended September 30, 2024 is set forth below:
| Weighted | ||||
|---|---|---|---|---|
| Weighted · average · Aggregate | ||||
| Outstanding | average | remaining | intrinsic | |
| stock | exercise | contractual | value | |
| options | price | life (years) | (in thousands) | |
| Balances as of December 31, 2023 | 14,268,055 | $4.40 | 6.27 | $118,757 |
| Granted | — | — | ||
| Exercised | (2,031,678) | 2.79 | ||
| Cancelled/forfeited | (489,975) | 10.85 | ||
| Balances as of September 30, 2024(1) | 11,746,402 | $4.41 | 5.50 | $53,606 |
| Exercisable as of September 30, 2024(2) | 11,104,045 | $4.00 | 5.39 | $55,239 |
(1)
As no forfeitures are estimated due to the Company’s adoption of ASU No. 2016-09, all options are vested or expected to vest. As of September 30, 2024, no options were outstanding that were subject to a future performance condition.
(2)
Exercisable shares include vested options as well as unvested shares that can be early exercised.
The aggregate intrinsic values of options are calculated as the difference between the exercise price of the options and the market price for shares of the Company’s Class A common stock as of each period-end. The total intrinsic value of options exercised for the nine months ended September 30, 2024 and 2023 was$12.6 million and$11.6 million, respectively.
No stock options were granted in the nine months ended September 30, 2024. Stock options granted during the nine months ended September 30, 2023 had a weighted average grant date fair value of$6.69 per share. The fair value of options granted is being expensed over the vesting period of the options on a straight-line basis as the services are being provided. No tax benefits were realized from options during the periods.
As of September 30, 2024, total unrecognized stock-based compensation expense related to options outstanding under the combined stock plans was$4.4 million. This unrecognized expense as of September 30, 2024 is expected to be recognized over the weighted average remaining vesting period of 1.98 years. As of September 30, 2024, the Company had 342,000 shares of non-employee stock options outstanding under the combined stock plans.
The fair value of each option granted to employees under the 2021 Plan is estimated on the grant date using the Black-Scholes pricing model.
Restricted Stock Units
RSUs granted under the 2021 Plan generally vest based on continued service. RSUs granted pursuant to the 2014 Plan vest according to a service condition as well as a performance condition, through a liquidity event, including (i) a change in control of the Company or (ii) the initial public offering of the Company’s equity securities, following which the securities shall be publicly traded, which includes a direct listing. As a result of the Direct Listing, the performance condition for all RSUs granted pursuant to the 2014 Plan has been met. During the three and nine months ended September 30, 2024, the Company recorded$21.2 million and$63.5 million in stock-based compensation related to RSUs, respectively. During the three and nine months ended September 30, 2023, the Company recorded$20.7 million and$55.9 million in stock-based compensation related to RSUs, respectively.
The total fair value of RSUs vested during the nine months ended September 30, 2024 and 2023 was$52.7 million and$42.2 million, respectively. As of September 30, 2024, total unrecognized stock-based compensation expense related to RSUs was$140.3 million. This unrecognized expense as of September 30, 2024 is expected to be recognized over the weighted average remaining vesting period of 2.12 years. As of September 30, 2024, the Company had 193,286 shares of non-employee RSUs outstanding under the combined stock plans.
RSU activity during thenine months ended September 30, 2024 was as follows:
| Restricted stockunits | Weighted-averagegrant date fair value per share | |
|---|---|---|
| Balance as of December 31, 2023 | 11,301,279 | $14.76 |
| Granted | 9,148,150 | 9.59 |
| Vested | (5,018,562) | 13.88 |
| Cancelled/forfeited | (2,472,264) | 13.54 |
| Balance as of September 30, 2024 | 12,958,603 | $11.68 |
2021 Employee Stock Purchase Plan
In August 2021, the Company’s board of directors adopted, and its stockholders approved, the 2021 Employee Stock Purchase Plan (the “ESPP”), which became effective in connection with the Direct Listing. The ESPP authorizes the issuance of shares of Class A common stock pursuant to purchase rights granted to employees. As of September 30, 2024, a total of 5,024,397 shares of the Company’s Class A common stock have been reserved for future issuance under the ESPP, in addition to any annual automatic evergreen increases in the number of shares of Class A common stock reserved for future issuance under the ESPP. The ESPP offers employees the option to purchase shares through a series of consecutive 12-month offering periods on each May 15th and November 15th (with two six-month purchase periods during each offering period). The price at which Class A common stock is purchased under the ESPP is equal to the lower of (i)85% of the closing trading price per share of the Company's Class A common stock on the first trading date of an offering period in which a participant is enrolled or (ii)85% of the closing trading price per share on the purchase date, which will occur on the last trading day of each purchase period, or such other price designated by the administrator.
The ESPP offers a rollover feature pursuant to which, if the fair market value of a share of Class A common stock on the first purchase date is lower than the fair market value on the first trading day of the offering period, the respective offering period will terminate and each participant will be automatically enrolled in the offering period that commences immediately following the purchase date. In accordance with the rollover feature, immediately following the conclusion of the purchase period ended May 14, 2024, the offering period was terminated and participants were automatically enrolled in a new 12-month offering period commencing on May 15, 2024 and ending on May 14, 2025. The impact of the rollover feature did not result in material incremental compensation cost for the nine months ended September 30, 2024.
As of September 30, 2024,1.1 million shares have been purchased under the ESPP. During the nine months ended September 30, 2024 and 2023, we issued 255,694 and 302,170 shares under the ESPP, respectively, in settlement of$2.0 million and$2.6 million of ESPP liabilities, respectively.
During the three and nine months ended September 30, 2024, the Company recognized$0.4 million and$1.2 million of stock-based compensation expense related to the ESPP, respectively. During the three and nine months ended September 30, 2023, the Company recognized$0.6 million and$1.9 million of stock-based compensation expense related to the ESPP, respectively. As of September 30, 2024, total unrecognized compensation cost related to the ESPP was$0.9 million, which will be amortized over a weighted average period of 0.60 years.
Stock-based compensation expense, net of actual forfeitures is reflected in the condensed consolidated statements of operations and comprehensive loss (in thousands):
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Cost of revenue | $1,559 | $1,947 | $4,581 | $5,426 |
| Research and development | 6,994 | 9,285 | 24,105 | 27,173 |
| Sales and marketing | 8,333 | 7,843 | 23,851 | 21,677 |
| General and administrative | 4,226 | 4,010 | 12,377 | 9,876 |
| Restructuring and other related charges | — | — | — | 853 |
| Total stock-based compensation expense | $21,112 | $23,085 | $64,914 | $65,005 |
(6)
Income Taxes
The Company had an effective tax rate of(4.6)% and(2.3)% for the three and nine months ended September 30, 2024, respectively, and(1.5)% and(1.0)% for the three and nine months ended September 30, 2023, respectively. The Company continues to incur U.S. operating losses and has minimal profits in its foreign jurisdictions.
During the three and nine months ended September 30, 2024 and 2023, the Company evaluated all available evidence, both positive and negative, including historical levels of income, and expectations and risks associated with estimates of future taxable income, and determined that it is more likely than not that its net deferred tax assets will not be realized in the United States. Due to uncertainties surrounding the realization of the deferred tax assets, the Company continues to maintain a full valuation allowance against its net deferred tax assets within the United States.
(7)
Operating Leases
Supplemental cash flow information related to operating leases was as follows (in thousands):
| Nine Months EndedSeptember 30, | |
|---|---|
| Right-of-use assets obtained in exchange for new operating lease liabilities | $— |
| Cash paid for operating lease liabilities | $3,719 |
Future minimum lease payments under non-cancellable operating leases with initial lease terms in excess of one year included in the Company’s lease liabilities as of September 30, 2024 were as follows (in thousands):
| Year ending December 31: | |
|---|---|
| Remainder of 2024 | 902 |
| 2025 | 3,384 |
| 2026 | 401 |
| 2027 | — |
| 2028 and thereafter | — |
| Total undiscounted operating lease payments | $4,687 |
| Less: imputed interest | (81) |
| Total operating lease liabilities | $4,606 |
(8)
Commitments and Contingencies
Legal Matters
On February 14, 2024, a putative securities class action captioned Chicago & Vicinity Laborers’ District Council Pension Fund v. Amplitude, Inc., et al., Case No. 3:24-cv-00898 (the “Securities Class Action”) was filed in the United States District Court for the Northern District of California, naming the Company, its Chief Executive Officer, and its former Chief Financial Officer as defendants. The lawsuit is purportedly brought on behalf of all those who purchased or acquired the Company’s common stock between September 21, 2021 and February 16, 2022. The complaint alleges claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, based on allegedly false or misleading statements related to the Company’s business and financial outlook. The lawsuit seeks unspecified damages and other relief. The defendants filed a motion to dismiss the complaint on July 12, 2024, which was granted with leave to amend on October 2, 2024. The plaintiffs filed an amended complaint on October 23, 2024.
On June 10, 2024, a shareholder derivative complaint captioned Hawkins v. Spenser Skates, et al., Case No. 3:24-cv-03460 (the “Derivative Action”) was filed in the United States District Court for the Northern District of California, naming the Company’s Chief Executive Officer, its former Chief Financial Officer, and the current and former members of the Company’s board of directors as defendants. The complaint, purportedly brought on behalf of the Company, alleges claims for breach of fiduciary duty, unjust enrichment, waste of corporate assets, abuse of control, gross mismanagement, and contribution for alleged wrongdoing by the Company’s directors and officers from September 21, 2021 through February 16, 2022. The complaint seeks unspecified damages and other relief. The Derivative Action is stayed pending a resolution of any motions to dismiss the Securities Class Action.
On August 8, 2024, a putative privacy class action captioned Atkins v. Amplitude, Inc., Case No. 3:24-cv-04913 was filed in the United States District Court for the Northern District of California, naming the Company as a defendant. The lawsuit is purportedly brought on behalf of all individuals who downloaded and used an application on their mobile device that embedded the Company’s Software Development Kit (“SDK”) and did not publicly disclose the Company in the application’s notices or disclosures. The complaint asserts claims under the Federal Wiretap Act, California Wiretap Act, California Invasion of Privacy Act, and California Comprehensive Computer Data Access and Fraud Act. The complaint seeks statutory damages and other relief. The Company filed a motion to dismiss the complaint on October 25, 2024.
On September 18, 2024, an individual privacy action captioned Shah v. Amplitude, Inc., Case No. 2:24-cv-08155-MEMF-JPR was filed in the United States District Court for the Central District of California, naming the Company as a defendant. The lawsuit is brought by an individual who alleges to have used an application on his mobile device that embedded the SDK without explicitly identifying the Company in the application’s notices or disclosures. The complaint asserts claims under the Federal Wiretap Act, California Wiretap Act, California Invasion of Privacy Act, and California Comprehensive Computer Data Access and Fraud Act. The complaint seeks statutory damages and other relief. On October 30, 2024, the Company and the plaintiff entered into a stipulation to stay the case pending final resolution of Atkins v. Amplitude, Inc., Case No. 3:24-cv-04913 (N.D. Cal.). The stipulation is pending court approval.
On October 7, 2024, a putative privacy class action captioned Willey v. Amplitude, Inc., Case No. 1:24-cv-07577 was filed in the United States District Court for the Southern District of New York. The lawsuit is purportedly brought on behalf of all persons who accessed the Oscar Health website or application in Pennsylvania and entered information in response to prompts in the “Find a Plan” function. The complaint alleges that the Company’s services operate on the Oscar Health website and application to intercept information submitted by users for a health insurance quote. The complaint asserts a claim under Pennsylvania’s Wiretapping and Electronic Surveillance Act. The complaint seeks unspecified damages and other relief.
The Company has received, and may in the future continue to receive, claims from third parties asserting, among other things, infringement of their intellectual property rights. Future litigation may be necessary to defend the Company, its partners and its customers by determining the scope, enforceability and validity of third-party proprietary rights, or to establish its proprietary rights.
In addition to the matters discussed above, from time to time, the Company is party to litigation and other legal proceedings in the ordinary course of business. While the Company does not believe the ultimate resolution of pending legal matters is likely to have a material adverse effect on its financial position, the results of any litigation or other legal proceedings are uncertain and as such the resolution of such legal proceedings, either individually or in the aggregate, could have a material adverse effect on its business, results of operations, financial condition or cash flows. The Company records litigation accruals for legal matters, which are both probable and estimable. For legal proceedings for which there is a reasonable possibility of loss (meaning those losses for which the likelihood is more than remote but less than probable), the Company has determined that it does not have material exposure, or it is unable to develop a range of reasonably possible losses. Although no assurance may be given, the Company believes that it is not presently a party to any litigation of which the outcome, if determined adversely, would individually or in the aggregate be reasonably expected to have a material and adverse effect on the business, operating results, cash flows, or financial position. Legal fees are expensed in the period in which they are incurred.
(9)
Net Loss Per Share
Basic net loss per share attributable to the Company’s common stockholders is computed in conformity with the two-class method required for participating securities. The rights, including the liquidation and dividend rights, of the holders of Class A and Class B common stock are identical, except with respect to voting, conversion, and transfer rights. As the liquidation and dividend rights are identical, all undistributed earnings are allocated on a proportionate basis to each class of common stock and the resulting basic and diluted net loss per share attributable to common stockholders are, therefore, the same for both Class A and Class B common stock on both an individual and a combined basis.
Basic net loss per share is computed by dividing the net loss attributable to the Company’s common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is the same as basic net loss per share for all periods presented because the effects of potentially dilutive items were anti-dilutive given the Company’s net loss position in each period presented.
The following table presents the calculation of basic and diluted net loss per share (in thousands, except per share data):
| Three Months EndedSeptember 30, | Nine Months EndedSeptember 30, | |||
|---|---|---|---|---|
| 2024 | 2023 | 2024 | 2023 | |
| Net loss attributable to Class A and Class B common stockholders | $(16,854) | $(17,747) | $(61,729) | $(71,820) |
| Weighted-average shares used in computing net loss per share attributable to Class A and Class B common stockholders, basic and diluted | 124,324 | 117,902 | 122,601 | 116,160 |
| Net loss per share attributable to Class A and Class B common stockholders, basic and diluted | $(0.14) | $(0.15) | $(0.50) | $(0.62) |
The following potential shares of common stock were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive for the periods presented (in thousands):
| As of September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Equity plan stock options outstanding | 11,746 | 14,942 |
| Equity plan stock options early exercised | — | 42 |
| RSUs outstanding | 12,959 | 11,661 |
| Restricted shares | — | 155 |
| Shares issuable pursuant to the ESPP | 694 | 498 |
| Total | 25,399 | 27,298 |
(10) Subsequent Events
RSU Awards
In October 2024, the Company issued 1.1 million RSUs to its employees with service-based vesting conditions. The service-based vesting condition for these awards are satisfied over three years. The grant date fair value of the RSUs issued in October 2024 was approximately $10.1 million.
Foobar Acquisition
On October 15, 2024 (the “Acquisition Date”), the Company acquired all the capital stock of Foobar, Inc. (“Acquiree”), a privately-held company for an aggregate of $23.9 million (net of cash acquired of $9.6 million), consisting of $17.0 million of net cash and $6.9 million of equity consideration through the issuance of 0.8 million shares of its common stock (the “Acquisition”). As part of the Acquisition, the Company agreed to certain equity payments with key employees in which an aggregate of 1.5 million shares with a value of $13.0 million that will be recognized as compensation expense.
The Acquisition is expected to enhance the Company’s digital analytics platform to drive customer success utilizing the Acquiree’s intuitive, AI-powered user assistance which makes complex software easier to adopt and navigate. The Acquisition will be accounted for as a business combination, but given the limited time that has passed since the Acquisition Date, the Company is still in the process of developing its fair value assumptions for the consideration, assets acquired, and liabilities assumed. As a result, we are unable to provide the amounts recognized as of the Acquisition Date for the major classes of assets acquired and liabilities assumed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.